Oskar Koperek

Dr. Oskar Koperek


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2011 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
KVKlemens Vierlinger
Klemens Vierlinger
MMMarkus H Mansfeld
Markus H Mansfeld
OOskar Koperek
Oskar Koperek
CNChrista Nöhammer
Christa Nöhammer
KKKlaus Kaserer
Klaus Kaserer
FLFriedrich Leisch
Friedrich Leisch
Several DNA microarray based expression signatures for the different clinically relevant thyroid tumor entities have been described over the past few years. However, reproducibility of these signatures is generally low, mainly due to study biases, small sample sizes and the highly multivariate nature of microarrays. While there are new technologies available for a more accurate high throughput expression analysis, we show that there is still a lot of information to be gained from data deposited in public microarray databases. In this study we were aiming (1) to identify potential markers for papillary thyroid carcinomas through meta analysis of public microarray data and (2) to confirm these markers in an independent dataset using an independent technology.

21 April 2011 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
OOskar Koperek
Oskar Koperek
OBOliver Bergner
Oliver Bergner
BPBettina Pichlhöfer
Bettina Pichlhöfer
FOFelicitas Oberndorfer
Felicitas Oberndorfer
JHJohannes A Hainfellner
Johannes A Hainfellner
PBPeter Birner
Peter Birner

4 May 2017 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
AKAumayr Klaus
Aumayr Klaus
OFOsmen Fathi
Osmen Fathi
TTTatjana Traub-Weidinger
Tatjana Traub-Weidinger
NBNiederle Bruno
Niederle Bruno
OOskar Koperek
Oskar Koperek

3 October 2013 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
OOskar Koperek
Oskar Koperek
EAErol Akin
Erol Akin
RAReza Asari
Reza Asari
BNBruno Niederle
Bruno Niederle
NNNikolaus Neuhold
Nikolaus Neuhold

19 August 2016 in APMIS
Verified
Journal Article
Closed access
PDF file
MHMerima Herac
Merima Herac
BNBruno Niederle
Bruno Niederle
MRMarkus Raderer
Markus Raderer
MKMichael Krebs
Michael Krebs
KKKlaus Kaserer
Klaus Kaserer
OOskar Koperek
Oskar Koperek

Verified
Journal Article
Open access
PDF file
TTTatjana Traub-Weidinger
Tatjana Traub-Weidinger
NPNina Poetsch
Nina Poetsch
AWAdelheid Woehrer
Adelheid Woehrer
EPEva-Maria Patronas
Eva-Maria Patronas
TBTatjana Bachnik
Tatjana Bachnik
OOskar Koperek
Oskar Koperek
Apart from its expression in benign and malignant prostate tissue, prostate specific membrane antigen (PSMA) was shown to be expressed specifically in the neovasculature of solid tumors. For gliomas only little information exists. Therefore, we aimed to correlate PSMA expression in gliomas to tumor metabolism by L-[S-methyl-11C]methionine (MET) PET and survival. Therefore, immunohistochemical staining (IHC) for isocitrate dehydrogenase 1-R132H (IDH1-R132H) mutation and PSMA expression was performed on the paraffin embedded tissue samples of 122 treatment-naive glioma patients. The IHC results were then related to the pre-therapeutic semiquantitative MET PET data and patients’ survival. Vascular PSMA expression was observed in 26 of 122 samples and was rather specific for high-grade gliomas ([HGG] 81% of glioblastoma multiforme, 10% of WHO grade III and just 2% of grade II gliomas). Significantly higher amounts of gliomas without verifiable IDH1-R132H mutation showed vascular PSMA expression. Significantly shorter median survival times were seen for patients with vascular PSMA staining in all tumors as well as HGG only. Additionally, significantly higher numbers of PSMA staining vessels were found in tumors with high amino acid metabolic rates. Vascular PSMA expression in gliomas was seen as a high-grade specific feature associated with elevated amino acid metabolism and short survival.